Global Gout Clinical Landscape Market Report 2020-2030 – ResearchAndMarkets.com

Global Gout Clinical Landscape Market Report 2020-2030 – ResearchAndMarkets.com




Global Gout Clinical Landscape Market Report 2020-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Gout” report has been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the Gout market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, a 10-year disease prevalence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The publisher estimates that in 2019, there were 35.4 million prevalent cases of gout in people aged 15 years and older worldwide, and forecasts that number to increase to 39.4 million prevalent cases by 2028.

The approved drugs in the gout space focus on targets such as microtubules, URAT1, xanthine oxidase, interleukin-1, and uric acid. These drugs are commonly administered via the oral route, with the remainder being available in intravenous and subcutaneous formulations.

The largest proportion of industry-sponsored drugs in active clinical development for gout are in Phase I, with just a single product in Phase III.

Drugs in development for gout focus on targets such as uric acid, URAT1, xanthine oxidase, and NLR protein-3/inflammasome. The largest proportion of pipeline drugs are administered via the oral route, with the remainder being intravenous, intramuscular, and topical formulations.

High-impact upcoming events for drugs in the gout space comprise topline Phase II trial results for Krystexxa, and topline Phase III trial results for SEL-212.

The overall likelihood of approval of a Phase I arthritis asset is 9.6%, and the average probability a drug advances from Phase III is 80.8%. Drugs, on average, take 9.1 years from Phase I to approval in the arthritis space, as well as in the overall autoimmune/immunology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for gout have been in the early and midphases of development, with 71% of trials in Phase I-II, and 29% in Phase III-IV.

The US has a substantial lead in the number of gout clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the gout space is dominated by completed trials. AstraZeneca has the highest number of completed clinical trials for gout, with 70 trials.

AstraZeneca leads industry sponsors with the highest overall number of clinical trials for gout.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Corticosteroids
  • Colchicine
  • Combination therapy
  • Prevention of chronic gout

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • SEL-212 for Gout (September 30, 2020)
  • URC102 for Gout (September 27, 2019)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Sobi Pays $100m Upfront For Selecta Gout Drug
  • Eisai Acquires Chinese Rights To Fuji Hyperuricemia Drug

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

Companies Mentioned

  • Ironwood
  • AstraZeneca

For more information about this report visit https://www.researchandmarkets.com/r/kv1n0v

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900